Treatment News : Study Suggests PrEP May Not Increase Overall Sexual Risk-Taking in Gay Men

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » April 2013

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


April 17, 2013

Study Suggests PrEP May Not Increase Overall Sexual Risk-Taking in Gay Men

Taking Truvada (tenofovir) as a pre-exposure prophylaxis (PrEP) to prevent HIV infection does not appear to increase overall sexual risk-taking among HIV-negative gay men, according to a study reported by aidsmap. The findings are clouded, however, by the fact that the participants received thorough HIV prevention counseling and services that may have counteracted inclinations to take greater sexual risks while relying on the apparent safety net of the drug.

A 2010 trial involving men who have sex with men found that Truvada lowered the risk of HIV infection by 44 percent on average, and that those with the greatest adherence—Truvada is supposed to be taken each day—saw a much better protective benefit.

Publishing their findings in the Journal of Acquired Immune Deficiency Syndromes, researchers studied 400 gay men for a 24-month period between 2005 and 2007 in this double-blind, placebo-controlled study.  

Participants were randomized into two groups, one that began Truvada immediately and another that did so nine months later. Researchers interviewed them at the outset and every three months thereafter about their sexual risk-taking and their use of recreational drugs and erectile dysfunction medications.  

At the beginning of the study, the group reported an average of 7.25 partners in the previous three months, a figure that dropped to 6 partners between months 3 and 9 and to 5.71 during the second year.  

Fifty-seven percent of the men reported unprotected anal intercourse during the three months before the study’s baseline, a proportion that dropped to 48 percent between months 3 and 9 and then rose to 52 percent in the second year.

At the baseline, 29 percent of men reported unprotected intercourse with another man they knew to be HIV positive. This figure dropped to 21 percent between months 3 and 9 and to 22 percent during the second year.

Men did not report a significant change in the number of reported episodes of anal sex overall.

Episodes of unprotected sex with partners known to be HIV positive dropped from 2 at the outset to 1.37 during the second year. Meanwhile, unprotected anal intercourse with partners believed to be HIV negative increased from 2.75 at baseline to 4 during year two, suggesting that men were “serosorting,” which is when individuals attempt to mitigate the risk of HIV transmission by favoring sex with those they believe share their HIV status.

It is entirely possible that the study’s findings are not representative of a real-world example of PrEP’s effect on gay men’s behavior, however. As the authors acknowledge, all the men in this study received risk-reduction counseling, condoms and lubricant, routine testing for HIV and sexually transmitted infections, and linkage to other prevention services, which the investigators write, “may explain the observed risk reduction and could explain the observed risk declines and could mitigate any potential for risk compensation.”

To read the aidsmap story, click here.

To read the study abstract, click here.

Search: PrEP, pre-exposure prophylaxis, Truvada, tenofovir, aidsmap, HIV, men who have sex with men, gay men, risk-taking, unprotected sex, serosorting.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Has a pet helped you deal with your HIV?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.